Prochlorperazine Maleate Versus Placebo for the Prophylaxis of Acute Mountain Sickness

Last updated: September 13, 2024
Sponsor: University of Colorado, Denver
Overall Status: Completed

Phase

2

Condition

N/A

Treatment

Prochlorperazine Maleate

Placebo

Clinical Study ID

NCT06450899
23-0958
  • Ages 18-75
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

This study is a trial looking at a drug to help prevent acute mountain sickness. The drug is prochlorperazine, a drug commonly used to treat nausea vomiting and headache. Participants will either take the drug or a placebo, and hike to and sleep at the summit of Mount Blue Sky located at 4,348 meters (14,265 feet).

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Adults >18 years old.

Exclusion

Exclusion Criteria:

  • Individuals <18 years old or >75 years old

  • Pregnant women

  • Individuals who reside at or have slept at elevations >1,800 meters in the last twoweeks

  • Individuals having taken acetazolamide, steroids, ibuprofen, anti-emetics oradditional analgesics within the last 24 hours prior to study initiation

  • Individuals requiring supplemental baseline oxygen or with chronic disorders knownto be significantly impacted by hypoxia

  • Individuals with known allergies to prochlorperazine or phenothiazines

  • Individuals taking medications with significant medication interactions withprochlorperazine: Dofetilide, potassium acid phosphate, potassium chloride,potassium citrate, potassium phosphate, Yohimbe.

  • Individuals with a history of dementia

  • Individuals who lack decision making capacity

Study Design

Total Participants: 57
Treatment Group(s): 2
Primary Treatment: Prochlorperazine Maleate
Phase: 2
Study Start date:
August 05, 2024
Estimated Completion Date:
August 28, 2024

Study Description

This study will be a double-blind randomized controlled trial to investigate the utility of prochlorperazine maleate versus placebo for the chemoprophylaxis of acute mountain sickness on rapid ascent to 4,348 meters, specifically the summit of Mount Blue Sky in the Mount Blue Sky Wilderness. Participants will be evaluated for AMS utilizing the 2018 LLQ both the evening of and morning after ascent. The primary outcome will be the presence of AMS, defined by a 2018 LLQ score equal to or greater than 3, including the presence of a headache at any measured point during the study. Individuals will convene the morning of the study in Golden, Colorado where they will receive breakfast and either placebo or prochlorperazine. They will then be driven to Summit Lake where they will break for lunch and receive the second dose of placebo or prochlorperazine. They will then hike to the Mount Blue Sky summit where they will receive their third and final dose of either placebo or intervention, spend the night in the structures at the summit, and be assessed for AMS via LLQ. In the morning, they will be assessed for AMS again, receive breakfast, and then be driven back to the original meeting point. They will be monitored by Emergency Physicians at all points during the study.

Connect with a study center

  • Mount Blue Sky

    Evergreen, Colorado 80439
    United States

    Site Not Available

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.